Article Text

Download PDFPDF


Molecular characterisation of oncogenic urothelial mosaic mutations in patients with extensive keratinocytic epidermal naevi

  1. Alejandra Gadea1,
  2. Inmaculada Hernandez-Munoz1,
  3. Asuncion Vicente2,
  4. Evelyn Andrades1,
  5. Miriam Garcia-Calvente3,
  6. Laura Camacho4,
  7. Conchi Fernandez-Rodriguez5,
  8. Beatriz Bellosillo4,6,
  9. Ramon Pujol1,7,
  10. Agustin Toll8
  1. 1
    Group of Inflammatory and Neoplastic Dermatological Diseases, IMIM, Barcelona, Catalunya, Spain
  2. 2
    Dermatology, Sant Joan de Deu Hospital, Barcelona, Catalunya, Spain
  3. 3
    Department of Medicine, University of Barcelona, Barcelona, Catalunya, Spain
  4. 4
    Department of Pathology, Hospital del Mar, Barcelona, Catalunya, Spain
  5. 5
    Department of Pathology, Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain
  6. 6
    Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Hospital del Mar, Barcelona, Catalunya, Spain
  7. 7
    Dermatology, Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain
  8. 8
    Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain
  1. Correspondence to
    Dr Agustin Toll, Dermatology, Hospital Clinic de Barcelona, Barcelona 08036, Spain; atoll{at}clinic.cat

Abstract

Background: Keratinocytic epidermal naevi (KENs) are congenital benign skin mosaic lesions that share common mutations with some subsets of urothelial carcinomas. Moreover, several patients with extensive KEN who also developed urothelial carcinomas at young ages have been reported. Thus, patients with extensive KEN may harbour mosaic urothelial oncogenic mutations that would favour the early development of urothelial carcinomas. Methods: We selected five patients with extensive KEN involving the lower part of the back and performed a molecular characterisation of urothelial and cutaneous samples using a next-generation sequencing (NGS) custom panel targeting candidate oncogenic genes. Results: Mosaic pathogenic mutations were detected in KEN in all patients. In four out of five patients, mosaic pathogenic mutations in FGFR2 or HRAS were also detected in samples from the urothelial tract. Moreover, we report a patient who developed urothelial carcinomas at age 29 and harboured an HRAS G12S mutation both in skin and urothelial tumour samples. Conclusions: We conclude that patients with extensive KEN involving the lower part of the back frequently harbour oncogenic mutations in the urothelium that may induce the development of carcinomas. NGS panels can be considered as highly sensitive tools to identify this subgroup of patients, which might permit adoption of screening measures to detect malignant transformation at early stages.

  • epidermal nevus
  • urothelial cancer
  • mosaicism
  • genetic screening/counselling

View Full Text

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.